Patents by Inventor Roland Contreras
Roland Contreras has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9359628Abstract: The present invention provides genetically engineered strains of Pichia capable of producing proteins with reduced glycosylation. In particular, the genetically engineered strains of the present invention are capable of expressing either or both of an ?-1,2-mannosidase and glucosidase II. The genetically engineered strains of the present invention can be further modified such that the OCH1 gene is disrupted. Methods of producing glycoproteins with reduced glycosylation using such genetically engineered stains of Pichia are also provided.Type: GrantFiled: January 10, 2014Date of Patent: June 7, 2016Assignees: VIB, VZW, Research Corporation Technologies, Inc., Universiteit GentInventors: Roland Contreras, Nico L.M. Callewaert, Steven C.J. Geysens
-
Patent number: 9028844Abstract: The present invention relates to a vaccine against Trypanosoma cruzi infection, useful in the prevention and/or treatment of the Chagas disease. More specifically, the present invention relates to a recombinant mutant trans-sialidase enzyme that can be used as an efficient vaccine, without side effects.Type: GrantFiled: March 14, 2007Date of Patent: May 12, 2015Assignees: VIB VZW, Universiteit GentInventors: Roland Contreras, Kristof De Vusser, Silvia Revelli
-
Publication number: 20140377804Abstract: A filamentous fungal cell having reduced UDP-galactofuranose is provided. The fungal cell may, in certain embodiments, contain a nuclear genome comprising an inactivated UDP-galactopyranose mutase (UDP-galp mutase) gene and a recombinant nucleic acid for expression of a protein. Also provided are methods of producing a protein using the subject fungal cell, as well as methods of producing the subject fungal cell.Type: ApplicationFiled: April 11, 2014Publication date: December 25, 2014Applicant: DANISCO US INC.Inventors: Michael Ward, Wouter Vervecken, Roland Contreras
-
Patent number: 8883445Abstract: The present invention provides genetically engineered strains of methylotrophic yeast including Pichia and especially Pichia pastoris capable of producing proteins with reduced or modified glycosylation. Methods of producing glycoproteins with reduced and/or modified glycosylation using such genetically engineered strains of Pichia are also provided. Vectors, which comprise coding sequences for ?-1,2-mannosidase I, glucosidase II, GlcNAc-tranferase I and mannosidase II or comprising OCH1 disrupting sequence, for transforming methylotrophic yeasts are contemplated by the present invention. Kit for providing the comtemplated vectors are also included in this invention.Type: GrantFiled: July 13, 2007Date of Patent: November 11, 2014Assignees: Research Corporation Technologies, Inc., Universiteit Gent, Vib, VZWInventors: Roland Contreras, Nico L. M. Callewaert, Steven C. J. Geysens, Vladimir Kaigorodov, Vervecken Wouter
-
Publication number: 20140154738Abstract: The present invention provides genetically engineered strains of Pichia capable of producing proteins with reduced glycosylation. In particular, the genetically engineered strains of the present invention are capable of expressing either or both of an ?-1,2-mannosidase and glucosidase II. The genetically engineered strains of the present invention can be further modified such that the OCH1 gene is disrupted. Methods of producing glycoproteins with reduced glycosylation using such genetically engineered stains of Pichia are also provided.Type: ApplicationFiled: January 10, 2014Publication date: June 5, 2014Applicants: VIB, VZW, UNIVERSITEIT GENT, RESEARCH CORPORATION TECHNOLOGIES, INC.Inventors: Roland Contreras, Nico L.M. Callewaert, Steven C.J. Geysens
-
Patent number: 8663971Abstract: The present invention provides genetically engineered strains of Pichia capable of producing proteins with reduced glycosylation. In particular, the genetically engineered strains of the present invention are capable of expressing either or both of an ?-1,2-mannosidase and glucosidase II. The genetically engineered strains of the present invention can be further modified such that the OCH1 gene is disrupted. Methods of producing glycoproteins with reduced glycosylation using such genetically engineered stains of Pichia are also provided.Type: GrantFiled: April 16, 2009Date of Patent: March 4, 2014Assignees: VIB, VZW, Research Corporation Technologies, Inc., Universiteit GentInventors: Roland Contreras, Nico L. M. Callewaert, Steven C. J. Geysens
-
Patent number: 8354268Abstract: The present invention provides genetically engineered strains of Pichiacapable of producing proteins with reduced glycosylation. In particular, the genetically engineered strains of the present invention are capable of expressing either or both of an ?-1,2-mannosidase and glucosidase II. The genetically engineered strains of the present invention can be further modified such that the OCH1 gene is disrupted. Methods of producing glycoproteins with reduced glycosylation using such genetically engineered stains of Pichia are also provided.Type: GrantFiled: September 25, 2003Date of Patent: January 15, 2013Assignees: VIB, VZW, Research Corporation Technologies, Inc., Universiteit GentInventors: Roland Contreras, Nico L. M. Callewaert, Steven C. J. Geysens
-
Patent number: 8058053Abstract: The present invention relates to methods and genetically engineered methylotrophic yeast strains for producing glycoproteins with mammalian-like glycosylation. The present invention also relates to vectors useful for generating methylotrophic yeast strains capable of producing glycoproteins with mammalian-like glycosylation. Glycoproteins produced from the genetically engineered methylotrophic yeast strains are also provided.Type: GrantFiled: February 11, 2009Date of Patent: November 15, 2011Assignees: VIB, VZW, Universiteit Gent, Research Corporation Technologies, Inc.Inventors: Roland Contreras, Nico L. M. Callewaert, Wouter Vervecken, Vladimir Kaigorodov
-
Publication number: 20110104750Abstract: A filamentous fungal cell having reduced UDP-galactofuranose is provided. The fungal cell may, in certain embodiments, contain a nuclear genome comprising an inactivated UDP-galactopyranose mutase (UDP-galp mutase) gene and a recombinant nucleic acid for expression of a protein. Also provided are methods of producing a protein using the subject fungal cell, as well as methods of producing the subject fungal cell.Type: ApplicationFiled: April 3, 2007Publication date: May 5, 2011Inventors: Michael Ward, Wouter Vervecken, Roland Contreras
-
Publication number: 20110038887Abstract: The present invention relates to a vaccine against Trypanosoma cruzi infection, useful in the prevention and/or treatment of the Chagas disease. More specifically, the present invention relates to a recombinant mutant trans-sialidase enzyme that can be used as an efficient vaccine, without side effects.Type: ApplicationFiled: March 14, 2007Publication date: February 17, 2011Applicants: VIB VZW, UNIVERSITEIT GENTInventors: Roland Contreras, Kristof De Vusser, Silvia Revelli
-
Publication number: 20100267084Abstract: The present invention provides genetically engineered strains of Pichia capable of producing proteins with reduced glycosylation. In particular, the genetically engineered strains of the present invention are capable of expressing either or both of an ?-1,2-mannosidase and glucosidase II. The genetically engineered strains of the present invention can be further modified such that the OCH1 gene is disrupted. Methods of producing glycoproteins with reduced glycosylation using such genetically engineered stains of Pichia are also provided.Type: ApplicationFiled: April 16, 2009Publication date: October 21, 2010Applicants: VIB, VZW, RESEARCH CORPORATION TECHNOLOGIES, INC.Inventors: Roland Contreras, Nico L. M. Callewaert, Steven C. J. Geysens
-
Publication number: 20090263863Abstract: The present invention relates to methods and genetically engineered methylotrophic yeast strains for producing glycoproteins with mammalian-like glycosylation. The present invention also relates to vectors useful for generating methylotrophic yeast strains capable of producing glycoproteins with mammalian-like glycosylation. Glycoproteins produced from the genetically engineered methylotrophic yeast strains are also provided.Type: ApplicationFiled: February 11, 2009Publication date: October 22, 2009Applicants: VIB, VZW, UNIVERSITEIT GENT, RESEARCH CORPORATION TECHNOLOGIES, INC.Inventors: Roland Contreras, Nico L. M. Callewaert, Wouter Vervecken, Vladimir Kaigorodov
-
Publication number: 20090098243Abstract: The present invention relates to a new isolated nucleic acid sequence comprising a gene that encodes a new fungal oxidase enzyme, and nucleic acid fragments thereof. It also relates to said new fungal oxidase isolated and purified from Aspergillus ficuum, its amino acid sequence as shown in SEQ ID NO 40 or 41, and functional equivalents or derivatives thereof. The present invention also relates to constructs, vectors and hosts cells comprising a nucleic acid molecule of the invention, as well as methods for producing an oxidase of the invention. The present invention also relates to the use of an oxidase of the invention in industrial processes.Type: ApplicationFiled: September 15, 2005Publication date: April 16, 2009Applicant: PURATOS N.V.Inventors: Filip Arnaut, Roland Contreras, Thierry Dauvrin, Guy Vanneste, Jasmine Viaene, Jacques Claude Eloi Georis
-
Publication number: 20090087882Abstract: The invention relates to the use of a glucosidase II mutation to increase protein secretion in yeast cells. The invention relates further to the use of yeast cells, comprising a mutant glucosidase II gene, possibly in combination with the expression of a recombinant ?-1,2-mannosidase gene and/or a recombinant N-acetylglucosaminyl-transferase gene, as a host for protein secretion.Type: ApplicationFiled: August 28, 2008Publication date: April 2, 2009Inventors: Roland Contreras, Steven Geysens
-
Patent number: 7507573Abstract: The present invention relates to methods and genetically engineered methylotrophic yeast strains for producing glycoproteins with mammalian-like glycosylation. The present invention also relates to vectors useful for generating methylotrophic yeast strains capable of producing glycoproteins with mammalian-like glycosylation. Glycoproteins produced from the genetically engineered methylotrophic yeast strains are also provided.Type: GrantFiled: November 14, 2003Date of Patent: March 24, 2009Assignees: VIB, vzw, Universiteit Gent, Research Corporation Technologies, Inc.Inventors: Roland Contreras, Nico L. M. Callewaert, Wouter Vervecken, Vladimir Kaigorodov
-
Patent number: 7491510Abstract: The present invention relates to the use of a glucosidase II mutation to increase protein secretion in eukaryotic cells. The present invention relates further to the use of eukaryotic cells, comprising a mutant glucosidase II gene, possibly in combination with the expression of a recombinant ?-1,2-mannosidase gene and/or a recombinant N-acetylglucosaminyl-transferase gene, as a host for protein secretion.Type: GrantFiled: September 12, 2005Date of Patent: February 17, 2009Assignees: Vlaams Interuniversitair Institute voor Biotechnologie vzw, Universiteit GentInventors: Roland Contreras, Steven Geysens
-
Publication number: 20080009037Abstract: The present invention provides genetically engineered strains of methylotrophic yeast including Pichia and especially Pichia pastoris capable of producing proteins with reduced or modified glycosylation. Methods of producing glycoproteins with reduced and/or modified glycosylation using such genetically engineered strains of Pichia are also provided. Vectors, which comprise coding sequences for ?-1,2-mannosidase I, glucosidase II, GlcNAc-tranferase I and mannosidase II or comprising OCH1 disrupting sequence, for transforming methylotrophic yeasts are contemplated by the present invention. Kit for providing the comtemplated vectors are also included in this invention.Type: ApplicationFiled: July 13, 2007Publication date: January 10, 2008Applicant: Flanders Interuniversity Institute For BiotechnologyInventors: Roland Contreras, Nico Callewaert, Steven Geysens, Vladimir Kaigorodov, Vervecken Wouter
-
Publication number: 20080003180Abstract: The present invention relates to a marker that can be used as aging biomarker. More specifically, the present invention relates to the analysis of N-glycans in serum and its relation to the virtual age of the subject. This aging biomarker can be used to study the effect of medication, food compounds and/or special diets on the wellness and virtual age of animals, including humans.Type: ApplicationFiled: November 29, 2005Publication date: January 3, 2008Applicants: Vlaams Interuniversitair Instituut Voor Biotechnologie VZW, Universiteit GentInventors: Cuiying Chen, Roland Contreras
-
Patent number: 7252933Abstract: The present invention provides genetically engineered strains of methylotrophic yeast including Pichia and especially Pichia pastoris capable of producing proteins with reduced or modified glycosylation. Methods of producing glycoproteins with reduced and/or modified glycosylation using such genetically engineered strains of Pichia are also provided. Vectors, which comprise coding sequences for ?-1,2-mannosidase I, glucosidase II, GlcNAc-tranferase I and mannosidase II or comprising OCH1 disrupting sequence, for transforming methylotrophic yeasts are contemplated by the present invention. Kit for providing the comtemplated vectors are also included in this invention.Type: GrantFiled: June 26, 2002Date of Patent: August 7, 2007Assignee: Flanders Interuniversity Institute for BiotechnologyInventors: Roland Contreras, Nico L. M. Callewaert, Steven C. J. Geysens, Vladimir Kaigorodov, Vervecken Wouter
-
Publication number: 20070010448Abstract: The present invention is concerned with the identification of genes or functional fragments thereof from Candida albicans which are critical for growth and cell division and which genes may be used as selective drug targets to treat Candida albicans associated infections. Novel nucleic acid sequences from Candida albicans are also provided and which encode the polypeptides which are critical for growth of Candida albicans. Methods for the identification of anti-fungal compounds which inhibit fungal or yeast growth are also contemplated.Type: ApplicationFiled: September 12, 2006Publication date: January 11, 2007Inventors: Roland Contreras, Bart Nelissen, Marianne De Backer, Walter Luyten, Jasmine Viaene, Marc Logghe, Jorge Vialard